Loading
NASDAQHealthcareBiotechnology
Latest quote
$10.835
+$0.335 · +3.19%
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Regular session
$10.835
+$0.335 · +3.19%
Regular session · ET · Market data may be delayed.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Day range
Current $10.835
52-week range
Current $10.835
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
62
Undervalued
Sentiment
65
Bullish
Risk
49
Elevated Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.
Day range
Current $10.835
52-week range
Current $10.835
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM16.48M0.02%77.7B USD0.19%$279.09+0.55%
First Trust Small Cap Growth AlphaDEX FundFYC6.53M0.49%1.77B USD0.70%$115.12+1.14%
iShares Biotechnology ETFIBB5.93M0.06%10.41B USD0.44%$206.6+3.05%
Vanguard Russell 2000 ETFVTWO4.77M0.03%18B USD0.06%$112.73+0.56%
iShares Russell 2000 Growth ETFIWO4.56M0.03%14.04B USD0.24%$356.84+0.95%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.76M0.10%2.64B USD0.20%$66.235+0.95%
Janus Henderson Small Cap Growth Alpha ETFJSML2.46M0.69%354.97M USD0.30%$87.69+1.25%
First Trust Small Cap Core AlphaDEX FundFYX2.4M0.18%1.67B USD0.58%$135.39+0.29%iShares Russell 2000 ETFIWMFirst Trust Small Cap Growth AlphaDEX FundFYCiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPJanus Henderson Small Cap Growth Alpha ETFJSMLFirst Trust Small Cap Core AlphaDEX FundFYXAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
